Behavioral interactions of simvastatin and fluoxetine in tests of anxiety and depression

Neuropsychiatric Disease and Treatment

Volumn 8, Issue , 2012, Pages 413-422

  Santos, Tainaê ^a   Baungratz, Monaliza Marizete ^a   Haskel, Suellen Priscila ^a   de Lima, Daniela Delwing ^b   da Cruz, Júlia Niehues ^c   Dal Magro, Débora Delwing ^a   da Cruz, José Geraldo Pereira ^a  

^a REGIONAL UNIVERSITY OF BLUMENAU   (Brazil)

^b UNIVERSITY OF JOINVILLE REGION   (Brazil)

^c UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

Author keywords

Elevated plus maze; Fluoxetine; Forced swimming test; Open field; Simvastatin

Indexed keywords

FLUOXETINE; PSIQUIAL; SIMVASTATIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ANXIETY; ARTICLE; CLIMBING; CONTROLLED STUDY; DEPRESSION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FORCED SWIMMING TEST; MALE; MAZE TEST; NONHUMAN; NORADRENERGIC SYSTEM; OPEN FIELD TEST; RAT; RISK ASSESSMENT; TRANQUILIZING ACTIVITY;

EID: 84867541290     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S31714     Document Type: Article

References (44)

1. Sett AK, Robinson TG, Mistri AK. Current status of statin therapy for stroke prevention. Expert Rev Cardiovasc Ther. 2011;9(10): 1305-1314.
2. Swindle JP, Potash J, Kulakodlu M, Kuznik A, Buikema A. Drug utilization patterns and cardiovascular outcomes in elderly patients newly initiated on atorvastatin or simvastatin. Am J Geriatr Pharmacother. 2011;9(6):471-482.
3. Wang Q, Zengin A, Deng C, et al. High dose of simvastatin induces hyperlocomotive and anxiolytic-like activities: The association with the up-regulation of NMDA receptor binding in the rat brain. Exp Neurol. 2009;216(1):132-138.
4. Zhang X, Tao Y, Troiani L, Markovic-Plese S. Simvastatin inhibits IFN regulatory factor 4 expression and Th17 cell differentiation in CD4+ T cells derived from patients with multiple sclerosis. J Immunol. 2011; 187(6):3431-3437.
5. Szasz BK, Mike A, Karoly R, et al. Direct inhibitory effect of fluoxetine on N-methyl-D-aspartate receptors in the central nervous system. Biol Psychiatry. 2007;62(11):1303-1309.
6. Bolo NR, Hodé Y, Nédélec JF, Lainé E, Wagner G, Macher JP. Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology. 2000;23(4):428-438.
7. Mayer A, Szasz BK, Kiss JP. Inhibitory effect of antidepressants on the NMDA-evoked [(3)H]noradrenaline release from rat hippocampal slices. Neurochem Int. 2009;55(6):383-388.
8. Durcan MJ, Lister RG, Eckardt MJ, Linnoila M. Behavioral interactions of fluoxetine and other 5-hydroxytryptamine uptake inhibitors with ethanol in tests of anxiety, locomotion and exploration. Psychopharmacology (Berl). 1988;96(4):528-533.
9. Robert G, Drapier D, Bentué-Ferrer D, Renault A, Reymann JM. Acute and chronic anxiogenic-like response to fluoxetine in rats in the elevated plus-maze: modulation by stressful handling. Behav Brain Res. 2011;220(2):344-348.
10. Rogóz Z, Skuza G. Anxiolytic-like effects of olanzapine, risperidone and fluoxetine in the elevated plus-maze test in rats. Pharmacol Rep. 2011;63(1):1547-1552.
11. Pittenger C, Sanacora G, Krystal JH. The NMDA receptor as a therapeutic target in major depressive disorder. CNS Neurol Disord Drug Targets. 2007;6(2):101-115.
12. Riaza Bermudo-Soriano C, Perez-Rodriguez MM, Vaquero-Lorenzo C, Baca-Garcia E. New perspectives in glutamate and anxiety. Pharmacol Biochem Behav. 2012;100(4):752-774.
13. Skolnick P, Popik P, Trullas R. Glutamate-based antidepressants 20 years on. Trends Pharmacol Sci. 2009;30(11):563-569.
14. Rogóz Z, Skuza G, Maj J, Danysz W. Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology. 2002;42(1): 1024-1030.
15. Pellow S, Chopin P, File SE, Briley M. Validation of open: closed arm entries in the elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods. 1985;14(3):149-167.
16. Prut L, Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol. 2003; 463(1-3):3-33.
17. Detke MJ, Rickels M, Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl). 1995;121(1): 66-72.
18. Cruz AP, Frei F, Graeff FG. Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol Biochem Behav. 1994;49(1):171-176.
19. Rodgers RJ, Cole JC. An ethological analysis of chlordiazepoxide and bretazenil (Ro 16-6028) in the murine elevated plus-maze. Behav Pharmacol. 1993;4(6):573-580.
20. Setem J, Pinheiro AP, Motta VA, Morato S, Cruz AP. Ethopharmacological analysis of 5-HT ligands on the rat elevated plus-maze. Pharmacol Biochem Behav. 1999;62(3):515-521.
21. Kalueff AV, Wheaton M, Murphy DL. What's wrong with my mouse model? Advances and strategies in animal modeling of anxiety and depression. Behav Brain Res. 2007;179(1):1-18.
22. Lister RG. Ethologically-based animal models of anxiety disorders. Pharmacol Ther. 1990;46(3):321-340.
23. Kalueff AV, Tuohimaa P. Grooming analysis algorithm for neurobehavioural stress research. Brain Res Brain Res Protoc. 2004; 13(3):151-158.
24. Rex A, Voigt JP, Gustedt C, Beckett S, Fink H. Anxiolytic-like profile in Wistar, but not Sprague-Dawley rats in the social interaction test. Psychopharmacol (Berl). 2004;177(1-2):23-34.
25. Poleszak E, Wlaź P, Szewczyk B, et al. A complex interaction between glycine/NMDA receptors and serotonergic/noradrenergic antidepressants in the forced swim test in mice. J Neural Transm. 2011; 118(11):1535-1546.
26. Kang S, Kim HJ, Kim HJ, et al. Effects of reboxetine and citalopram pretreatment on changes in cocaine and amphetamine regulated transcript (CART) expression in rat brain induced by the forced swimming test. Eur J Pharmacol. 2010;647(1-3):110-116.
27. Porsolt RD, Anton G, Deniel M, Jalfre M. Behavioral despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol. 1978;47(4):379-391.
28. Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol. 1997; 8(6-7):523-532.
29. López-Rubalcava C, Lucki I. Strain differences in the behavioral effects of antidepressant drugs in the rat forced swimming test. Neuropsychopharmacology. 2000;22(2):191-199.
30. Page ME, Detke MJ, Dalvi A, Kirby LG, Lucki I. Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the forced swimming test. Psychopharmacology (Berl). 1999;147(1):162-167.
31. Rénéric JP, Bouvard M, Stinus L. Idazoxan and 8-OH-DPAT modify the behavioral effects induced by either NA, or 5-HT, or dual NA/5-HT reuptake inhibition in the rat forced swimming test. Neuropsychopharmacology. 2001;24(4):379-390.
32. Renshaw PF, Parsegian A, Yang CK, et al. Lovastatin potentiates the antidepressant efficacy of fluoxetine in rats. Pharmacol Biochem Behav. 2009;92(1):88-92.
33. Haenisch B, Bönisch H. Depression and antidepressants: insights from knockout of dopamine, serotonin or noradrenaline re-uptake transporters. Pharmacol Ther. 2011;129(3):352-368.
34. Pruus K, Rudissaar R, Allikmets L, Harro J. The effect of the NMDA receptor antagonist dizocilpine on behavioral manifestations of serotonin and adrenergic antidepressants in rats. Methods Find Exp Clin Pharmacol. 2010;32(2):123-128.
35. Mori-Okamoto J, Namii Y, Tatsuno J. Subtypes of adrenergic receptors and intracellular mechanisms involved in modulatory effects of noradrenaline on glutamate. Brain Res. 1991;539(1):67-75.
36. Kirsch C, Eckert GP, Mueller WE. Statin effects on cholesterol micro-domains in brain plasma membranes. Biochem Pharmacol. 2003;65(5): 843-856.
37. Mok SW, Thelen KM, Riemer C, et al. Simvastatin prolongs survival times in prion infections of the central nervous system. Biochem Biophys Res Commun. 2006;348(2):697-702.
38. Schoonjans K, Peinado-Onsurbe J, Fruchart JC, Tailleux A, Fiévet C, Auwerx J. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase. FEBS Lett. 1999;452(3):160-164.
39. Selley ML. Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced striatal dopamine depletion and protein tyrosine nitration in mice. Brain Res. 2005;1037(1-2):1-6.
40. Vega GL, Weiner MF, Lipton AM, et al. Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch Neurol. 2003;60(4):510-515.
41. Johnson-Anuna LN, Eckert GP, Keller JH, et al. Wood WG. Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. J Pharmacol Exp Ther. 2005;312(2):786-793.
42. Kiss JP, Szasz BK, Fodor L, et al. GluN2B-containing NMDA receptors as possible targets for the neuroprotective and antidepressant effects of fluoxetine. Neurochem Int. 2012;60(2):170-176.
43. Machado-Vieira R, Ibrahim L, Henter ID, Zarate CA Jr. Novel glutamatergic agents for major depressive disorder and bipolar disorder. Pharmacol Biochem Behav. 2012;100(4):678-687.
44. Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 2012;62(1):63-77.